Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108
ssanders@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Aug. 29, 2011

Generic Drug Manufacturers Should Be Able to Warn of Products’ Risks, Public Citizen Tells FDA

To Improve Drug Safety, FDA Should Revise Outdated Regulations That Prevent Generic Drugmakers From Updating Product Labeling and Immunize Them from Liability

WASHINGTON, D.C. – The Food and Drug Administration (FDA) should revise its regulations to allow generic drug manufacturers to update product labeling to warn patients about risks associated with their drugs, Public Citizen said in a petition sent today to the agency.

Under current FDA regulations, generic manufacturers cannot update their products’ labeling, even if they become aware of a potential risk not stated in the labeling. In contrast, brand-name drug manufacturers can update warnings and precautions on product labeling before getting FDA approval. The generic drugmaker is required to match its labeling to brand-name labeling.

Over the past 25 years, the sale of generic drugs has skyrocketed. Today, generics constitute the majority of all prescriptions filled. As of 2010, 90 percent of prescriptions for drugs with generic versions were filled with a generic, rather than a brand-name, drug. In light of this shift, generic companies have access to a great deal of information about product safety and effectiveness and should have the same ability as brand-name companies to revise labeling to give physicians and patients the best available information about the safety of their products, the petition said.

The illogical disparity between labeling regulations for generic companies and brand-name companies was highlighted in a June 2011 decision of the U.S. Supreme Court. In PLIVA v. Mensing, the court relied on FDA regulations as the basis for its holding that patients harmed by inadequate warnings on a generic drug cannot sue the drugmaker for damages, while people who take brand-name version of the same drug can. This “absurd consequence,” to quote Justice Sonia Sotomayor, turned on the fact that FDA regulations do not allow generic manufacturers to alter their labeling, even when they become aware that it is inadequate.

“Drug safety would benefit if generic manufacturers – who already have access to real-world information about adverse events – could use FDA procedures currently in place for brand-name manufacturers to revise labeling to warn of risks,” said Dr. Sidney Wolfe, director of Public Citizen Health Research Group. “Filling this regulatory gap would help to protect patients.”

The FDA has limited resources to monitor the tens of thousands of drugs on the market, especially considering funding and staff shortages at the agency. Accordingly, the FDA always has relied on drugmakers to identify previously unknown risks.

Public Citizen submitted an amicus brief in PLIVA v. Mensing, arguing that it is vital for all drug manufacturers, including generic drug manufacturers, to have incentives to respond to new safety information because potential hazards often do not become apparent until years after a drug has been on the market.

“The action we are requesting would bring FDA regulation in line with the realities of the pharmaceutical market and help to ensure that drug labeling provides adequate warnings to patients based on information that comes to light after the drug is approved for marketing,” said Allison Zieve, director of the Public Citizen Litigation Group.

The petition submitted today also urges the FDA to reiterate generic drugmakers’ obligation to inform the FDA whenever the manufacturer becomes aware of information suggesting an association between the product and a hazard not adequately disclosed on the labeling.

Read Public Citizen’s amicus brief in PLIVA v. Mensing.

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.